THE LANDMARK TRIAL PENN STATE, 6 MONTHS, PEER-REVIEWED: A 6-month randomized, double-blind, placebo-controlled human trial of 54 adults at Penn State University (Richie et al., European Journal of Nutrition, 2015) found that oral Setria L-Glutathione at 250 mg/day produced significant increases in whole-blood glutathione levels at 1, 3, and 6 months versus baseline establishing for the first time that oral glutathione is bioavailable in humans
Extended-release exenatide (Bydureon BCise) has an apparent terminal half-life of approximately 2 weeks due to its depot formulation, with drug concentrations potentially persisting for 8-10 weeks after discontinuation
Time-course studies can be performed to monitor dynamic changes in GSH/GSSG under stress, treatment, or process conditions, helping identify critical inflection points in redox balance
Contrave is used for long-term weight management without the same classification